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Abstract
 .Liposomes were prepared from phospholipid mixtures of dipalmitoylphosphatidylcholine DPPC and phosphatidylinosi-
 .  .  .tol PI , encapsulating the enzymes glucose oxidase GO and GO in combination with horse radish peroxidase HRP by
 .  .both extrusion VET and reverse-phase evaporation REV . The optimum level of PI in DPPCrPI liposomes for targeting
to biofilms of the oral bacterium Streptococcus gordonii has been established. The liposomes were characterised in terms of
the content and activity of the encapsulated enzymes. The antibacterial activity of these ‘reactive’ liposomes arising from
hydrogen peroxide and oxyacids in the presence of the substrates glucose and iodide ions, after targeting to the biofilms,
were measured both as a function of liposome-biofilm incubation time and incubation time with the substrates. Bacterial
inhibition increases with both liposome-biofilm and substrate-biofilm incubation time and with the extent of enzyme
encapsulation. The reactive liposomes also display antibacterial activity in the presence of saliva. The reactive liposomes
have potential value in the context of oral hygiene.
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1. Introduction
It has been demonstrated that phospholipid lipo-
somes can be targeted to bacteria either by incorpora-
tion of particular lipids such as phosphatidylinositol
 . w x w xPI 1–4 and stearylamine 5–7 or by surface-bound
w x w xlectins 1,4,8 or antibodies 9 . There have been a
number of examples of the delivery of bactericides to
w w xbacteria by liposomes, specifically Triclosan 1,10 ,
w x w x w xvancomycin 11 , ciprofloxacin 12 , gentamicin 13
w xand ampicillin 14 and the use of liposomes as
delivery systems in the treatment of infections has
w xbeen reviewed by Bergers et al. 15 .
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In the field of cosmetics, toiletries and oral hy-
giene the exploitation of ‘natural’ bactericidal or
bacteriostatic systems is a desirable aim. Natural
antibacterial systems arising from hydrogen peroxide
decomposition by peroxidase enzymes such as lacto-
peroxidase and myeloperoxidase are present in milk,
w xtears and saliva 16,17 . The antibacterial activity of
the lactoperoxidase-hydrogen peroxidase-thiocyanate
system has been studied extensively by Thomas et al.
 w x.see, e.g., Refs. 18,19 and shown to be effective
w xagainst oral streptococci 20,21 and in combination
with glucose oxidase a commercial preservative sys-
 .tem Myavert C for cosmetics and toiletries has been
w xdeveloped 22 .
In this work we report an investigation to exploit
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targeted liposomes encapsulating the coupled enzyme
 .system glucose oxidase GO –horse radish peroxi-
 .dase HRP as an antibacterial system against the oral
bacterium Streptococcus gordonii formerly S. san-
w x.guis CR2b 23 , using glucose as the primary sub-
strate together with iodide. The combination of hy-
 .  y.drogen peroxide H O and iodide I results in2 2
  .the production of oxyacids hypoiodous HIO , iodic
 .  ..HIO and periodic HIO which have antibacterial3 4
properties. The reaction scheme may be summarised
as follows:
GO
glucose “ H O qgluconic acid lactone 1 .2 2
HRP yH O “ H Oq IO “other oxyacids2 2 2yI
The reactive liposomes were prepared from mix-
tures of DPPC and PI, by both reverse phase evapora-
 w x.  w x.tion REV 24 and extrusion VETs 25 , encapsu-
lating GO alone and in combination with HRP and
were targeted to biofilms of the bacterium on mi-
crotitre plates.
2. Materials and methods
L-a-Dipalmitoylphosphatidylcholine DPPC, prod-
. uct No. P0763 , glucose oxidase GO, Type VII-S,
. product no. G7016 , horse radish peroxidase HRP,
.Type 1, product no. P8125 and o-dianisidine tablets
 .product no. D9154 were obtained from Sigma,
 .Poole, Dorset, UK. Phosphatidylinositol PI from
wheat germ, grade I was from Lipid Products, South
w3 x  .Nutfield, UK. H DPPC spec. act. 55 Cirmmol
was from Amersham International, Amersham, UK.
 .Bacteriological agar No. 1 code L11 , brain heart
 .infusion BHI, code M 255 , yeast extract powder
 .  .code L 21 and phosphate-buffered saline PBS
 .tablets code BR 14a were from Oxoid Ltd, Bas-
 .ingstoke, Hants, UK. Casein product no. 44020 was
 .from British Drug Houses BDH Poole, Dorset, UK.
Filters for preparing VETs were from Poretics, Liver-
more CA, USA. Chloroform and methanol Analar
.grade were from BDH, they were distilled before use
and stored over molecular sieves type 4A from Fisons
Plc, Loughborough, UK. All other reagents were
made up with double-distilled water.
2.1. Preparation and characterisation of liposomes
encapsulation enzymes
REV were prepared by a modification of the
w xmethod of Szoka and Papahadjopoulos 24 , DPPC
 .  .27 mg plus the desired amount of PI 1–10 mg and
w3 x  .H DPPC 5 mCi was dissolved in 3 ml of chloro-
 .form-methanol 4:1 by volume in a 50-ml round-bot-
tomed flask. The organic phase was removed by
rotary evaporation at 608C and the resulting film was
 .dispersed in chloroform-methanol 4:1 by volume
 .and 3 ml of buffer solution PBS containing the
desired enzyme mixture total concentration 1 mg
y1.ml previously held at 608C. The mixture was
gently shaken and then sonicated for 5 min using a
 .bath sonicator Decon FS100 . The resulting homoge-
neous emulsion was rotary evaporated at 608C until
 .an aqueous suspension formed approx. 10 min . The
suspension was purged with nitrogen for 15 min at
608C and kept at 608C for a further 15 min to anneal
the REV.
VETs were prepared by dissolving the required
 .lipid mixtures as for REV in 3 ml of chloroform-
 .methanol 4:1 by volume in a 500-ml round-bot-
tomed flask. Following rotary evaporation to form a
thin lipid film, the film was dispersed in 3 ml of
nitrogen-saturated PBS containing the required en-
zymes at 608C and vigorously agitated to form multi-
 .lamellar vesicles MLV . The MLVs were extruded
10= through two stacked polycarbonate 100 nm
pore size Poretic filters at a pressure of 200 psi.
To remove unencapsulated enzymes the REV and
VETs were fractionated by Sepharose 4B gel filtra-
tion. The liposome fractions were assayed for lipid by
w3 xliquid scintillation counting of H DPPC and for
w xprotein by a Lowry microassay 26 . The size distri-
bution of the liposomes was determined by photon
 .correlation spectroscopy PCS using a Malvern Au-
tosizer, model no. RR146.
2.2. Enzyme acti˝ity in reacti˝e liposomes
The activities of GO, GO co-encapsulated with
HRP and HRP co-encapsulated with GO were as-
sayed both before and prior to disruption of the
liposomes with Triton X-100 and the results com-
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pared with the initial activities of the enzymes. The
assays were based on the HRP catalysed oxidation of
o-dianisidine by H O . The method for the assay of2 2
GO using o-dianisidine in combination with HRP
with glucose as the substrate was a modification of a
w xpreviously described method 27 as was the assay of
w xHRP 28 with H O as substrate. GO co-encapsu-2 2
lated with HRP was assayed using glucose and o-di-
anisidine without additional HRP. HRP alone and in
the presence of GO was assayed with o-dianisidine
plus H O in the absence of glucose. The assay2 2
procedures for GO and HRP were as follows.
 .For GO, 12 ml of phosphate buffer 0.1 M pH 6
 .was mixed with 100 ml o-dianisidine 1% wrv to
 .give a stock dye solution. Aliquots 2.5 ml of dye
 .solution, 300 ml glucose solution 18% wrv , 100
 y1.ml HRP 60 units ml and 100 ml of liposome
sample were mixed and the absorbance was measured
at 460 nm for 2–4 min against a blank containing no
liposomes. The activity of the GO was calculated
from the relation
DA rmin460nmGO activity unitsrmg s 2 .  .
11.3= mgGOrml .
where the extinction coefficient of oxidised o-di-
anisidine is 11.3=103 My1 cmy1. For assays in the
presence of Triton X-100 the liposomes were dis-
rupted by the addition of 100 ml of 1 mM Triton
X-100, the dye solution volume being reduced to 2.4
ml.
For HRP the assay mixture contained 300 ml
 .phosphate buffer 0.1 M, pH 6.0 , 300 ml of H O2 2
 . 0.01 M , 50 ml o-dianisidine 0.02 M in methanol
.freshly prepared 2.25 ml of water and 50 ml of
liposome sample. The absorbance was followed as
for GO using a blank containing no liposomes. For
assays in the presence of Triton X-100 the liposomes
were disrupted by addition of 50 ml of 1 mM Triton
X-100. The HRP activity was calculated from the
equation
DA rmin460nmHRP activity unitsrmg s .
11.3= mg HRPrml .
3 .
For the assay of GO coencapsulated with HRP and
HRP co-encapsulated with GO the total protein con-
tent of the liposomes was assayed by the Lowry
w xmicroassay 25 and it was assumed that there was no
change in the mass ratio of the enzymes from that in
the initial mixture in order to determine their activi-
 .  .ties from Eq. 2 and Eq. 3 .
2.3. Growth of bacteria
 .Brain heart infusion BH1, 3.7 g was mixed in
100 ml of water and 1.5 g of bacteriological agar
added. The mixture was boiled to dissolve the agar
and sterilized by autoclaving 15 lbs pressure, 15
.  .min . Defibrinated horse blood 5% vrv was added
and the resulting mixture used to charge sterile Petri
dishes which were then incubated at 378C for 15 min.
The plates were inoculated with S. gordonii and
incubated for 18 h at 378C in a candle jar. The
bacterial colonies were used to inoculate sterile
growth medium containing 3.7 g BHI, 0.3 g yeast
extract powder, 2 g sucrose in 100 ml of water
divided between 10 screwtops jars. The jars were
placed in a candle jar and incubated at 378C for 18 h.
The cell suspensions were centrifuged 2000 rpm for
.5 min, MSE super minor with swing-out rotor to
pellet the cells and the supernatant discarded. The
cells were resuspended in PBS at 48C and re-pelleted
and the process repeated 3= and the cells finally
diluted to give an absorbance of 0.5 at 550 nm.
2.4. Targeting of liposomes to biofilms
 . Aliquots 200 ml of S. gordonii suspension ab-
.sorbance 0.5 at 550 nm were incubated in the wells
 .of microtitre plates Dynatech M1298 for 18 h at
room temperature. After incubation the bacterial sus-
pension was removed and the remaining immobilised
biofilm was washed twice with sterile PBS and blot-
ted dry by inversion. Potential vacant binding sites
were then blocked with 300 ml of 0.02% wrv casein
in PBS for 30 min at room temperature followed by
 .2=300 ml PBS washes. Aliquots 200 ml of lipo-
somes were incubated with the biofilms at 378C for 2
h, after which the liposome suspensions were re-
moved and the wells washed 3=with 300 ml PBS
and blotted dry. The biofilm was dispersed by addi-
 .tion of 220 ml sodium n-dodecylsulphate 1% wrv
followed by a brief sonication and incubated for 30
 .min at room temperature. Aliquots 200 ml were
( )K.J. Hill et al.rBiochimica et Biophysica Acta 1326 1997 37–4640
taken for scintillation counting. Control wells con-
taining only bacteria, only PBS and only liposomes
suspensions were used to monitor background levels
of activity. The results of the targeting assay are
expressed in terms of percentage apparent monolayer
 .coverage % amc given by
Nobs% amcs =100 4 .
La
where N is the observed number of mol of lipidobs
adsorbed to the biofilm and L is the number of mola
of lipid which would be absorbed if the film was
covered with a close-packed layer of liposomes. La
was calculated from the equation.
A bfL s N 5 .a w2
p d r2 /w
where d is the weight average diameter of thew
liposomes having a weight average number of lipid
molecules per liposome of N and A is the geo-w bf
metric area of the biofilm. For unilamellar liposomes
N can be calculated from d assuming an area perw w
lipid molecule in the liposomal bilayer taken as 50
2.  .nm and a bilayer thickness taken as 7.5 nm as
w xpreviously described 29 . The area of the biofilm
was taken as 2.202=10y4 m2 which was measured
in a previous study for the surface of microtitre plate
w xwells exposed to 200 ml of solution 30 .
2.5. Antibacterial acti˝ity of reacti˝e ˝esicles
S. gordonii biofilms were prepared as described in
Section 2.4. Liposomes were added to the wells 200
.  .ml at 378C for the desired time period 1 to 60 min .
Following incubation, the plate wells were emptied of
liposomes suspension and washed 2= with sterile
 .PBS and blotted dry. Glucose, 200 ml 18% wrv
was added followed by 50 ml of sodium iodide
solution at the required concentration to give a final
concentration in the range 1–10 mM. The exposure
time to glucose and iodide was varied from 1 to 30
min. Addition of 1 M glucose shrinks the liposomes
by approx. 20%, but we have no evidence that they
do not remain intact in the presence of 1 M glucose.
After the required incubation time the plate was
washed 2= with sterile PBS and blotted dry. Sterile
 .nutrient broth 200 ml was added to each well and
the plate incubated for 18 h at 378C in a candle jar.
The absorbance of each well was measured at 630
nm using a Dynatech MR 610 plate reader coupled to
an Apple IIe microcomputer. The increase in ab-
sorbance over the 18-h period was taken as a measure
of bacterial growth. Controls used were bacteria-in-
cubated with PBS followed by broth which gave
maximal bacterial growth, bacteria-free wells with
PBS or liposomes exposed to glucose and iodide
which were taken as the background level. Controls
with enzyme-free liposomes were also carried out
 .see Fig. 6 . These showed that some inhibition of
growth could arise with ‘empty’ liposomes, which
was significant, particularly for short liposome-bio-
 .film incubation times 1 min . When sterilized human
saliva was used instead of iodide this was pooled
saliva from 10 donors, stored on ice and clarified by
 .centrifugation 10 000=g for 5 min . It was steril-
ized by heat treatment and diluted to 10% using PBS.
3. Results
3.1. Targeting of DPPC-PI liposomes to S. gordonii
biofilms
To establish the optimum level of PI in DPPC-PI
liposomes for targeting to the biofilms, a range of
REVs and VETs were prepared in which the PI
content of the bilayer was varied from approx. 3 to
20 mol%. Figs. 1 and 2 show the apparent monolayer
coverage for REVs and VETs respectively. For both
types of liposome, targeting was optimal at approx.
17 mol% PI although for the VETs the optimum was
not as sharply defined as for the REVs. The optimum
composition for targeting was used in all subsequent
studies.
3.2. Characterisation of DPPC-PI liposomes encap-
sulating enzymes
Table 1 shows the size and extents of enzyme
encapsulation for the liposomes. For the REVs the
average encapsulation of GO was 24.3"2.5% of the
initial protein, for GOrHRP mixtures in REVs 28.6
"4.1% and for GOrHRP mixtures in VETs 4.06"
0.62%. The figures for REVs suggest that the extent
of encapsulation is the same within experimental
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Fig. 1. Dependence of adsorption of DPPCrPI REV liposomes to
Streptococcus gordonii biofilms on mol% PI content. The lipo-
somes in PBS were incubated with the biofilm for 2 h. The
liposomal lipid concentration was 0.3 mM and the average
 .weight average diameter d was 186 nm.w
error for GO and GOqHRP, suggesting that the
enzymes are being encapsulated independently, the
amount of encapsulation being determined by the
liposome internal volume. The amount of protein
encapsulated increases with protein to lipid ratio;
however, the % encapsulation is independent of the
Fig. 2. Dependence of adsorption of DPPCrPI VETs to Strepto-
coccus gordonii biofilms on mol% PI content. The liposomes in
PBS were incubated with the biofilm for 2 h. The liposomal lipid
concentration was 0.3 mM and the average weight average
 .diameter d was 112 nm.w
initial protein to lipid concentration ratio in the ap-
proximate range 45 to 180 mg protein per mmol of
lipid. These observations suggest that while the inter-
nal volumes of the liposomes are not saturated with
protein there are limits to the % encapsulation attain-
able under the conditions of preparation. The ratio of
Table 1
  ..Characterisation of liposomes composition DPPC-PI 17 mol % encapsulating enzymes
 .Liposome type Enzyme wt ratio Initial mg protein per Final mg protein per d nm % Encapsulationw
GO:HRP mmol of lipid mmol of lipid
REV 1:0 45.12 11.91 212 26.4
REV 1:0 67.68 13.98 218 20.7
REV 1:0 90.24 22.97 210 25.5
REV 1:0 135.4 33.49 178 24.7
REV 1:1 45.12 11.21 215 24.9
REV 1:1 90.2 23.82 208 26.4
REV 1:0.7 112.8 40.00 224 35.5
REV 1:1 135.4 39.19 218 28.9
REV 1:1 180.5 48.81 199 27.1
VET 1:1 45.12 2.19 97 4.84
VET 1:0.5 67.68 3.01 103 4.45
VET 1:1 90.24 3.61 98 4.00
VET 1:1.5 112.8 3.63 108 3.22
VET 1:0.7 112.8 4.30 106 3.81
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Table 2
  ..Enzymic activities in free solution and encapsulated in VETs DPPC-PI 17 mol%
y1 y1 .  .Enzyme wt ratio Enzyme Initial solution activity Encapsulated activity units mg Activity units mg % recovery
y1 .GO:HRP assayed units mg prior to Triton X-100 release after Triton X-100 release of activity
1:0 GO 69.3"2.2 4.85"1.01 71.1"3.2 103
0:1 HRP 246.1"11.4 43.4"5.21 191.7"12.4 77.8
1:1 GO 69.3"2.2 9.12"0.23 52.8"9.4 76.2
1:1 HRP 246.1"11.4 61.8"29.7 271.6"76.7 110
the internal volumes of the REVs to the VETs is on
 .3average 209r102 s8.6, so from the average %
 .encapsulation of the VETs 4.06% the REVs would
be expected to encapsulate 35% of the protein which
compares with the observed values of, on average
27"4%. This disprepancy may arise from some
multilamellarity of the REVs which would lead to a
smaller internal diameter and volume and hence a
smaller extent of encapsulation.
The enzymic activities of the enzymes after encap-
sulation relative to their initial values were assessed
and shown in Table 2. For GO and HRP encapsulated
Fig. 3. Antibacterial activity to Streptococcus gordonii biofilms
of REVs encapsulation GO as a function of the liposome-biofilm
incubation time and the exposure time of the liposome-biofilm to
1 M glucose. The liposomal lipid concentration was 0.3 mM,
 .y1encapsulated protein concentration 26.47 mg mmole lipid ,
REV weight average diameter d s215 nm.w
independently after treating the liposomes with Triton
X-100, the recovery of activity was 103 and 78%
respectively. Recovery was also high after coencapsu-
lation of the enzymes. The low figures for the activity
of the enzymes before Triton treatments possibly
arose from the disruption of a small proportion of the
liposomes during the assay. The results demonstrate
that there was no major loss in enzymic activity
during encapsulation.
Fig. 4. Antibacterial activity to Streptococcus gordonii biofilms
 .of VETs encapsulating GOrHRP mass ratio 1:1 as a function
of the liposome-biofilm incubation time and the concentration of
 .iodide ions in the presence of glucose 1 M . The liposome-bio-
film system was exposed to glucose and iodide for 10 min. The
liposomal lipid concentration was 0.3 mM, encapsulated protein
 .y1concentration 3.61 mg mmol lipid , VET weight average
diameter d s98 nm.w
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3.3. Antibacterial acti˝ity of liposomes encapsulating
enzymes
The antibacterial activity of the reactive liposomes
 .encapsulating GO alone Fig. 3 and in combination
with HRP was assessed as a function of the time of
exposure of biofilm to the liposomes and the time in
the presence of the enzyme substrates glucose and
 .iodide ions Figs. 4–6 and glucose in the presence of
 .saliva Fig. 7 . Fig. 3 shows the antibacterial activity
of liposomes encapsulating GO increases with the
time of incubation of the biofilm with the liposomes
 .and the time of exposure to the substrate glucose .
For this system the bactericidal action will come only
from hydrogen peroxide. Fig. 4 shows the anti-
bacterial activity of reactive liposomes containing
both GO and HRP in the presence of iodide ions. The
activity of the reactive VETs increases between 1 and
5 mM iodide concentration, remaining constant above
5 mM iodide. Using an iodide concentration of 5
mM, the activity of reactive REVs after various times
of exposure to substrates are shown in Fig. 5 and the
Fig. 5. Antibacterial activity to Streptococcus gordonii biofilms
 .of REVs encapsulating GOrHRP mass ratio 1:1 as a function
of liposome-biofilm incubation time and the time of incubation
 .  .with glucose 1 M and iodide ions 5 mM . The liposomal lipid
concentration was 0.3 mM, encapsulated protein concentration
y1 .23.82 mg mmol lipid , REV weight average diameter d sw
208 nm.
Fig. 6. Antibacterial activity to Streptococcus gordonii biofilms
 .of VETs encapsulating GOrHRP mass ratio 1:1 as a function
of liposome-biofilm incubation time and time of incubation with
 .  .glucose 1 M and iodide ions 5 mM . The liposomal lipid
concentration was 0.3 mM, encapsulated protein concentration
y1 .3.63 mg mmol lipid , VET weight average diameter d s108w
nm. The three bars to the right of each group are data for
enzyme-free VETs, liposomal lipid concentration 0.3 mM VET
weight average diameter d s102 nm.w
corresponding data for reactive VETs in Fig. 6. Also
shown in Fig. 6 are the effects of enzyme-free lipo-
somes on growth inhibition. Some inhibition was
observed by ‘empty’ liposomes, but this was signifi-
cantly smaller than the effects of liposomes-encapsu-
lating enzyme.
Comparison of the data in Fig. 3 for REVs encap-
sulating only GO with the data in Fig. 5 for REVs
encapsulating both GO and HRP shows that the
coupled enzyme system is more effective at inhibit-
ing growth for shorter times of exposure of the
biofilms to the liposomes; e.g., for 1- and 10-min
exposure times followed by 60 min in contact with
substrate, the REV-GO liposomes inhibit 7.7% and
12.30% respectively, whereas the REV-GOrHRP li-
posome inhibit 34.2% and 37.1% respectively. For
 .long exposure times 30 min , both systems show
similar inhibition effects.
Comparison of the data for REV and VETs encap-
sulating GOqHRP in Figs. 5 and 6 show that the
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Fig. 7. Antibacterial activity to Streptococcus gordonii biofilms
 .of VETs encapsulating GOrHRP mass ratio 1:1 as a function
of liposome-biofilm incubation time and time of incubation with
 .  .glucose 1 M and saliva 10% . The liposomal lipid concentra-
tion was 0.3 mM encapsulated protein concentration 4.29 mg
y1 .mmol lipid , VET weight average diameter d s106 nm.w
REV are more antibacterial than the VETs for the
 .shorter exposure times 1 and 10 min of liposomes
to biofilm. It should be noted that the enzyme content
of the REV is considerably larger 23.82 mgrmmol
.  .lipid than the VETs 3.63 mgrmmol lipid .
Fig. 7 shows that the reactive liposomes have
significant antibacterial activity in the presence of
saliva with only glucose as the substrate. The iodide
 w x.level in saliva is very low 13.8"8.5 mM 31 and
would not be expected to play a significant role;
however, bacteriostatic activity from hypothiocyanite
 -.ions OSCN arising from the oxidation of thio-
cyanate, a substrate for lactoperoxidase in saliva,
w xwould be expected to arise 21 since the thiocyanate
concentration in saliva is relatively high at 1.2"0.7
w xmM 31 .
4. Discussion
The objectives of this study were to prepare and
characterise reactive liposomes which would both
target to bacterial biofilms and, in the presence of
appropriate substrates, inhibit subsequent bacterial
growth. The coupled enzyme system selected, glu-
cose oxidase plus horse radish peroxidase in the
presence of glucose and halide ion produces hydro-
gen peroxide which oxidises iodide ions to oxyacids.
Both hydrogen peroxide and the oxyacids have anti-
bacterial activity to oral streptococci. The data in
Figs. 1 and 2 show that the incorporation of PI into
the bilayer of DPPC liposomes effectively targets the
liposomes to Streptococcus gordonii and the opti-
mum level of PI is the same for both liposomes
 .prepared by extrusion VETs and reverse-phase
 .evaporation REV , although the extent of adsorption
 .% apparent monolayer coverage is greater for REV
than for VETs. It is possible that the higher apparent
monolayer coverage found for REV may arise as a
consequence of a higher degree or percentage of
multilamillarity in these preparations. The reason for
the existence of an optimum PI level for liposome
targeting to biofilm has been discussed previously
w x2,4 . The optima arise as a consequence of possibly
hydrogen bonding interactions both within and be-
tween the polyhydroxy head groups of the liposomal
lipids and the teichoic acids in the bacterium surface.
Consideration of these interactions on the basis of a
w xlattice model 2 shows that there is a balance be-
tween ‘self-interactions’ within the liposome and bac-
terium surfaces and ‘cross-interactions’ between the
surfaces. Such a model predicts that there is an
 .optimum level of polyhydroxy lipid PI at which the
cross-interactions predominate over the self-interac-
tions which can give rise to a minimum in the
potential energy-separation curve and hence a maxi-
mum in the extent of adsorption.
Both types of liposome were produced in which
the enzymes were encapsulated. There is no evidence
to suggest for the coupled enzyme system that both
enzymes do not encapsulate in the proportion present
in the initial mixture used for encapsulation. The data
in Table 2 demonstrate that the enzymic activity is
substantially similar in the aqueous core of the lipo-
somes to that in free solution and is largely recovered
after disruption of the liposomes with Triton X-100.
The reactive liposomes have antibacterial activity
towards biofilms of Streptococcus gordonii. The re-
growth assay of activity involved initial adsorption of
the liposomes on the biofilm, a period of incubation
with substrates, followed by addition of growth
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medium. Antibacterial activity will depend on the
extent of adsorption of the liposomes to the biofilm
and the generation and action of bactericidal or bacte-
riostatic species during the period of incubation with
substrates. The function of the reactive liposomal
system is two-fold: retention of the enzymes in close
contact with the biofilm and the production of bacte-
rial growth inhibitors. The data clearly show that the
extent of growth inhibition depends on the time of
incubation of the liposomes with the biofilm. It is
also dependent on the enzyme content of the lipo-
 .somes REV inhibit more than VETs and would be
expected to be proportional to the extent of targeting
to the biofilm. Thus to a first approximation, assum-
ing a constant time of incubation with substrates, we
may expect the % inhibition to be given by a relation
of the form
% inhibitionsC E t targeting % 6 .
w xwhere E is the enzyme concentration in the lipo-
w xsomes, t the time of exposure of the liposomes to
the biofilm and C is the constant of proportionality.
 .Eq. 6 assumes that targeting increases in proportion
to the time of liposome-biofilm incubation so that the
apparent monolayer coverage at short times is propor-
tional to that at saturation. It is also assumed that the
liposomes remain intact on adsorption to the biofilms,
Fig. 8. Inhibition of bacterial growth from Streptococcus gor-
w xw x w xdonii biofilms as a function of the parameter E t targeting %
 .see text .
as suggested by previous studies on proteoliposomes
w x32 , and hence the substrates react within the lipo-
somes to produce the bactericidal species which dif-
fuse out into the biofilms. Fig. 8 shows a test of Eq.
 .6 for the different systems studied, all the data
relating to a 60-min incubation with substrates. It is
seen that for the VETs the % inhibition increases in
w xw x w xproportion to the parameter E t targeting % . The
REV data suggest that for these liposomes, inhibition
has almost reached limiting values. Only for the
liposomes incorporating the single enzyme GO does
inhibition increase markedly with time of exposure of
 .liposomes to biofilm Fig. 3 , indicating that the
reactivity of these liposomes is below the limiting
value.
In practical terms the experiments cover the realis-
tic situation of a brief exposure of the biofilm to the
reactive liposomes followed by a longer period of
exposure to natural substrates, as might be conceived
during use of a preparation for oral hygiene. Such
reactive liposomes may also exploit substrates pre-
 .sent in saliva for their antibacterial activity Fig. 7 .
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